\u201cGrindeks\u201d akt\u012bvo farmaceitisko vielu ra\u017eo\u0161anas noda\u013cas vad\u012bt\u0101ja Raimonda Auzi\u0146a viedoklis.<\/p>\n\n\n\n
Z\u0101\u013cu defic\u012bts Eirop\u0101 vairs nav tikai atsevi\u0161\u0137u valstu vesel\u012bbas apr\u016bpes sist\u0113mas probl\u0113ma. P\u0113d\u0113jos gados tas k\u013cuvis par Eiropas Savien\u012bbas m\u0113roga z\u0101\u013cu pieg\u0101des dro\u0161\u012bbas jaut\u0101jumu. \u012apa\u0161a uzman\u012bba tiek piev\u0113rsta akt\u012bvaj\u0101m farmaceitiskaj\u0101m viel\u0101m (AFV) jeb API (active pharmaceutical ingredients angl. val.<\/em> ) \u2013 viel\u0101m, kas nodro\u0161ina z\u0101\u013cu farmakolo\u0123isko iedarb\u012bbu un bez kur\u0101m gala z\u0101\u013cu ra\u017eo\u0161ana nav iesp\u0113jama. K\u0101 stiprin\u0101t API ra\u017eo\u0161anas jaudas Eirop\u0101 \u0161\u0101br\u012b\u017ea glob\u0101l\u0101s nenoteikt\u012bbas apst\u0101k\u013cos un mazin\u0101t z\u0101\u013cu pieg\u0101des riskus?<\/strong><\/p>\n\n\n\n Z\u0101\u013cu ra\u017eo\u0161anai Eirop\u0101 j\u0101b\u016bt ekonomiski dz\u012bvotsp\u0113j\u012bgai<\/strong><\/p>\n\n\n\n Eiropas Komisijas (EK) 2025. gad\u0101 public\u0113taj\u0101 anal\u012bz\u0113 secin\u0101ts, ka aptuveni 75 % \u0137\u012bmisko API ra\u017eo\u0161anas vietu atrodas \u0101rpus Eiropas Savien\u012bbas (ES), galvenok\u0101rt Indij\u0101 un \u0136\u012bn\u0101. Savuk\u0101rt aptuveni 21 % no analiz\u0113taj\u0101m akt\u012bvaj\u0101m farmaceitiskaj\u0101m viel\u0101m ES nav nevienas ra\u017eo\u0161anas vietas1<\/sup>. Tas noz\u012bm\u0113, ka atsevi\u0161\u0137u z\u0101\u013cu ra\u017eo\u0161an\u0101 Eiropa ir piln\u012bb\u0101 atkar\u012bga no tre\u0161o valstu pieg\u0101d\u0113m, ko \u012bpa\u0161i izj\u016btam glob\u0101lo satricin\u0101jumu laik\u0101.<\/p>\n\n\n\n \u0160\u0101da situ\u0101cija izveidojusies ekonomisku iemeslu d\u0113\u013c \u2013 \u0100zij\u0101 ra\u017eotas API var b\u016bt par vismaz 20\u201340 % l\u0113t\u0101kas nek\u0101 Eirop\u0101 ra\u017eot\u0101s2<\/sup>. Ra\u017eo\u0161anu Eirop\u0101 sad\u0101rdzina ener\u0123ijas, darbasp\u0113ka un vides pras\u012bbu izmaksas, savuk\u0101rt lielie \u0100zijas ra\u017eot\u0101ji ieg\u016bst ar\u012b no ra\u017eo\u0161anas apjoma. Rezult\u0101t\u0101 daudzu pla\u0161i lietotu un sal\u012bdzino\u0161i l\u0113tu z\u0101\u013cu ra\u017eo\u0161anas \u0137\u0113des vair\u0101ku gadu desmitu laik\u0101 ir koncentr\u0113ju\u0161\u0101s \u0101rpus Eiropas.<\/p>\n\n\n\n Zem\u0101kas cenas nevar v\u0113rt\u0113t atrauti no pieg\u0101des dro\u0161\u012bbas. Ja konkr\u0113tu z\u0101\u013cu akt\u012bv\u0101 viela tiek ra\u017eota tikai da\u017e\u0101s r\u016bpn\u012bc\u0101s vai vien\u0101 \u0123eogr\u0101fiskaj\u0101 re\u0123ion\u0101, ra\u017eo\u0161anas probl\u0113mas, kvalit\u0101tes neatbilst\u012bba, lo\u0123istikas trauc\u0113jumi vai eksporta ierobe\u017eojumi var vienlaikus ietekm\u0113t z\u0101\u013cu pieejam\u012bbu vair\u0101k\u0101s valst\u012bs. Un kas notiek br\u012bd\u012b, kad valstis, kur\u0101s notiek \u0161o vielu ra\u017eo\u0161ana, savu domin\u0113jo\u0161o poz\u012bciju s\u0101k izmantot k\u0101 ekonomisku vai politisku sviru?<\/p>\n\n\n\n Tie\u0161i \u0161\u012bs atkar\u012bbas mazin\u0101\u0161anai ES maina pieeju z\u0101\u013cu pieg\u0101des dro\u0161\u012bbai. 2026. gada maij\u0101 tika pan\u0101kta provizoriska vieno\u0161an\u0101s par Kritiski svar\u012bgo z\u0101\u013cu aktu, kura m\u0113r\u0137is ir palielin\u0101t kritiski svar\u012bgu z\u0101\u013cu un to akt\u012bvo vielu ra\u017eo\u0161anas jaudu ES, da\u017e\u0101dot pieg\u0101des avotus un mazin\u0101t p\u0101rm\u0113r\u012bgu atkar\u012bbu no tre\u0161aj\u0101m valst\u012bm. Virziens ir pareizs, ta\u010du ar politisku ap\u0146em\u0161anos vien nepietiek, \u2013 lai m\u0113s patie\u0161\u0101m atg\u016btu liel\u0101ku kontroli p\u0101r savu z\u0101\u013cu pieg\u0101des \u0137\u0113di, j\u0101sp\u0113j rad\u012bt apst\u0101k\u013ci, kuros akt\u012bvo farmaceitisko vielu ra\u017eo\u0161ana Eirop\u0101 ir ar\u012b konkur\u0113tsp\u0113j\u012bga.<\/p>\n\n\n\n Stingr\u0101kas pras\u012bbas vis\u0101 pieg\u0101des \u0137\u0113d\u0113<\/strong><\/p>\n\n\n\n Izmai\u0146as paredz\u0113tas publiskajos z\u0101\u013cu iepirkumos. L\u012bdz \u0161im cena daudzos tirgos bijusi viens no galvenajiem konkurences faktoriem, kas Eiropas ra\u017eot\u0101jiem apgr\u016btin\u0101ja konkurenci ar zem\u0101ku izmaksu ra\u017eot\u0101jiem no tre\u0161aj\u0101m valst\u012bm. Regul\u0113jums paredz\u0113s, ka kritiski svar\u012bgu z\u0101\u013cu iepirkumos j\u0101\u0146em v\u0113r\u0101 ar\u012b pieg\u0101des notur\u012bba. Krit\u0113rijiem j\u0101veicina akt\u012bvo vielu pieg\u0101des avotu da\u017e\u0101do\u0161ana un j\u0101nov\u0113rt\u0113 uzticami pieg\u0101d\u0101t\u0101ji, pieg\u0101des termi\u0146i, kr\u0101jumi un pieg\u0101des \u0137\u0113des p\u0101rvald\u012bba.<\/p>\n\n\n\n V\u0113l konkr\u0113t\u0101ks meh\u0101nisms pl\u0101nots gad\u012bjumos, kad kritiski svar\u012bgu z\u0101\u013cu pieg\u0101des \u0137\u0113d\u0113 konstat\u0113ta augsta atkar\u012bba no vienas vai da\u017e\u0101m tre\u0161aj\u0101m valst\u012bm. \u0160\u0101dos gad\u012bjumos publiskajos iepirkumos b\u016bs j\u0101veicina ra\u017eo\u0161ana ES. Cits meh\u0101nisms \u013caus pie\u0161\u0137irt papildu punktus pied\u0101v\u0101jumam, kur\u0101 vismaz 50 % attiec\u012bg\u0101 l\u012bguma apjoma veido ES ra\u017eotas kritiski svar\u012bg\u0101s z\u0101les un to akt\u012bv\u0101s vielas3<\/sup>.<\/p>\n\n\n\n Nepiecie\u0161ama koordin\u0113ta pieeja ra\u017eo\u0161anas jaudu palielin\u0101\u0161anai<\/strong><\/p>\n\n\n\n Vai jaunie regul\u0113juma meh\u0101nismi noz\u012bm\u0113, ka tikai Eiropa var vai tai b\u016btu j\u0101ra\u017eo API pa\u0161ai? \u012as\u0101 atbilde ir \u2013 n\u0113. Ieviestie pas\u0101kumi ir \u201cplats solis\u201d, tom\u0113r to praktisk\u0101 \u012bsteno\u0161ana joproj\u0101m ir izaicin\u0101jums. Atsevi\u0161\u0137\u0101m API Eirop\u0101 pa\u0161laik nav alternat\u012bvu ra\u017eo\u0161anas jaudu, savuk\u0101rt jaunu jaudu izveide vai ra\u017eo\u0161anas atjauno\u0161ana prasa laiku un finan\u0161u resursus. T\u0101p\u0113c l\u012bdz ar ra\u017eo\u0161anas stiprin\u0101\u0161anu Eirop\u0101 b\u016btiska ir ar\u012b pieg\u0101d\u0101t\u0101ju un \u0123eogr\u0101fisko avotu diversifik\u0101cija, k\u0101 ar\u012b p\u0101rredzama sadarb\u012bba ar valst\u012bm \u0101rpus ES.<\/p>\n\n\n\n Vienlaikus pa\u0161laik nav vienotas datub\u0101zes, kas \u013cautu nov\u0113rt\u0113t API faktiskos ra\u017eo\u0161anas apjomus, br\u012bv\u0101s ra\u017eo\u0161anas jaudas un ra\u017eot\u0101ju specializ\u0101ciju katr\u0101 dal\u012bbvalst\u012b. Da\u013ca \u0161\u012bs inform\u0101cijas, protams, ir komerci\u0101li sensit\u012bva, tom\u0113r vienotas sist\u0113mas tr\u016bkums apgr\u016btina kop\u012bgu risku nov\u0113rt\u0113\u0161anu, invest\u012bciju piesaisti un vienotas pieejas veido\u0161anu.<\/p>\n\n\n\n Eirop\u0101 sara\u017eoto API \u012bpatsvara palielin\u0101\u0161ana pati par sevi z\u0101\u013cu defic\u012btu neatrisin\u0101s, turkl\u0101t katr\u0101 dal\u012bbvalst\u012b izveidot pilnu visu nepiecie\u0161amo akt\u012bvo vielu ra\u017eo\u0161anas ciklu nav nepiecie\u0161ams. Z\u0101\u013cu pieg\u0101des notur\u012bba liel\u0101 m\u0113r\u0101 b\u016bs atkar\u012bga no dal\u012bbvalstu, regulatoru un farm\u0101cijas uz\u0146\u0113mumu sp\u0113jas sadarboties. Lab\u0101ka inform\u0101cijas aprite par ra\u017eo\u0161anas iesp\u0113j\u0101m, koordin\u0113tas invest\u012bcijas un vair\u0101ku neatkar\u012bgu API pieg\u0101des avotu veido\u0161ana ES var mazin\u0101t atkar\u012bbu no atsevi\u0161\u0137iem \u0101r\u0113jiem pieg\u0101d\u0101t\u0101jiem un risku, ka trauc\u0113jumi vien\u0101 re\u0123ion\u0101 izraisa glob\u0101lu z\u0101\u013cu defic\u012btu. Ar\u012b \u201cGrindeks\u201d att\u012bsta sadarb\u012bbas iesp\u0113jas ar Eiropas farm\u0101cijas uz\u0146\u0113mumiem API ra\u017eo\u0161anas jom\u0101. Vienlaikus nepiecie\u0161ama ar\u012b politiska iz\u0161\u0137ir\u0161an\u0101s par to, k\u0101 rad\u012bt apst\u0101k\u013cus, kuros ra\u017eo\u0161ana Eirop\u0101 sp\u0113j konkur\u0113t ar l\u0113t\u0101k\u0101m \u0100zijas API izejviel\u0101m.<\/p>\n\n\n\n Avoti:<\/strong><\/p>\n\n\n\n 1<\/sup> COMMISSION STAFF WORKING DOCUMENT Summarising evidence supporting the legislative proposal laying a framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicines of common interest and amending Regulation (EU) 2024\/795 https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?qid=1780974906583&uri=CELEX%3A52025SC0263<\/a><\/p>\n\n\n\n 2<\/sup> COMMISSION STAFF WORKING DOCUMENT Vulnerabilities of the global supply chains of medicines – Structured Dialogue on the security of medicines supply https:\/\/eur-lex.europa.eu\/legal-content\/LV\/TXT\/?uri=CELEX:52023SC0020<\/a><\/p>\n\n\n\n 3<\/sup> Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL laying a framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest, and amending Regulation (EU) 2024\/795 https:\/\/data.consilium.europa.eu\/doc\/document\/ST-11059-2026-INIT\/en\/pdf<\/a><\/p>\n\n\n\n <\/p>\n","protected":false},"excerpt":{"rendered":" \u201cGrindeks\u201d akt\u012bvo farmaceitisko vielu ra\u017eo\u0161anas noda\u013cas vad\u012bt\u0101ja Raimonda Auzi\u0146a viedoklis. Z\u0101\u013cu defic\u012bts Eirop\u0101 vairs nav tikai atsevi\u0161\u0137u valstu vesel\u012bbas apr\u016bpes sist\u0113mas probl\u0113ma. P\u0113d\u0113jos gados tas…<\/p>\n","protected":false},"author":22,"featured_media":12854,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-12852","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/12852","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/22"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=12852"}],"version-history":[{"count":2,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/12852\/revisions"}],"predecessor-version":[{"id":12863,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/12852\/revisions\/12863"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/12854"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=12852"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=12852"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=12852"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}